gilead sanofi - Search News

News

Sanofi, Gilead Sciences and Kymera

Kymera Shrugs Off Sanofi Bust With Gilead Deal--But There Are Caveats

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers hope. Click for my GILD and KYMR update.

Yahoo Finance · 2h

Kymera’s partnerships with Sanofi and Gilead drive value

Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs.

BioPharma Dive · 1d

Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a new drug prospect, meanwhile.

Fierce Biotech8h

Gilead blames low RSV infection rates last season for scrapping 2 obeldesivir trials

Gilead has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two mid-stage trials of ...

Zacks Investment Research on MSN1d

KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update

Kymera Therapeutics, Inc. KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader ...

Fierce Pharma20h

GSK, Gilead, Novo Nordisk join other Big Pharmas in honoring 2025 LGBTQ+ Pride month

A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, ...

Medical Marketing & Media5h

Rx Rundown: Royalty Pharma, Gilead Sciences, Abridge and more

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results